Oxomemazine

PHARMACOKINETICS

Absorption
Oxomemazine had been absorbed following oral administration. Its systemic exposure had depended on gastrointestinal uptake and the extent of first-pass processing. After oral dosing, the drug had entered the systemic circulation and produced its pharmacological effects.

Distribution
Following absorption, oxomemazine had been distributed throughout the body and had reached the central nervous system. Its passage across the blood–brain barrier had been responsible in part for the sedative effects associated with the drug. Distribution within tissues and binding to plasma proteins had influenced its pharmacokinetic behavior.

Metabolism
Oxomemazine had been metabolized mainly in the liver. Hepatic biotransformation had converted the drug into metabolites that were subsequently cleared from the body. The precise metabolic pathways in humans had not been characterized as extensively as those of some other antihistamines.

Elimination
Oxomemazine and its metabolites had been cleared through renal and biliary pathways. Metabolic products had been removed from the circulation, with urinary excretion contributing to the overall elimination of the drug.

PHARMACODYNAMICS

Oxomemazine acted mainly by blocking histamine H1 receptors, which reduced histamine-mediated allergic symptoms such as sneezing, itching, runny nose, and watery eyes. It also showed antitussive activity and produced a sedative effect through its action on the central nervous system. Its anticholinergic activity further contributed to a reduction in certain secretions.

ADMINISTRATION

Oxomemazine was given by mouth, usually in the form of an oral solution or syrup. The required quantity was measured accurately with a suitable measuring device. Administration was adjusted according to the patient's age and clinical requirements. Since the drug could cause drowsiness, activities requiring full attention and coordination were approached with caution.

DOSAGE AND STRENGTH

Oxomemazine was mainly supplied as an oral liquid, and the available strength varied among products. The dosage depended on the patient's age, body weight, and the condition being treated. In children, the dose was selected carefully according to age and weight, and the recommended amount was not exceeded.

DRUG INTERACTIONS

Oxomemazine could increase the sedative effects of alcohol and other central nervous system depressants, including opioids, benzodiazepines, and sleep-inducing medicines. Its anticholinergic effects could also become stronger when used with other anticholinergic drugs. Such combinations could increase drowsiness, reduce alertness, and affect coordination, so concurrent use required caution.

FOOD INTERACTIONS 

Oxomemazine could be administered with or without food, as food was not expected to cause a major change in its therapeutic effect. Because the medicine could produce drowsiness and reduced alertness, alcohol and other substances with sedative properties were avoided to reduce the possibility of excessive central nervous system depression.

CONTRAINDICATIONS

Oxomemazine was not used in individuals who had a known allergy or hypersensitivity to oxomemazine or related phenothiazine compounds. Its use was also contraindicated or avoided in conditions where its sedative or anticholinergic actions could worsen the patient's condition. These included severe respiratory depression, urinary retention, narrow-angle glaucoma, and pronounced central nervous system depression. Particular care was required when it was considered for young children because excessive sedation and respiratory complications could occur.

SIDE EFFECTS

Treatment with oxomemazine was associated mainly with effects related to sedation and anticholinergic activity. Reported effects included drowsiness, dizziness, weakness, dry mouth, blurred vision, constipation, and difficulty passing urine. Headache, nausea, vomiting, and decreased alertness could also occur. In less common cases, patients could develop confusion, hypersensitivity reactions, abnormal movements, or other neurological disturbances. More serious or persistent reactions required appropriate medical evaluation.

OVERDOSE

Excessive intake of oxomemazine could cause significant depression of the central nervous system. Patients experiencing an overdose could develop pronounced sleepiness, confusion, reduced consciousness, or, in severe cases, coma. Other possible findings included low blood pressure, an increased heart rate, respiratory depression, abnormal movements, and anticholinergic manifestations such as marked dryness of the mouth and urinary retention. Management was primarily supportive and involved maintaining adequate airway, breathing, and circulation while closely observing vital functions.

TOXICITY

Oxomemazine toxicity was mainly characterized by excessive sedative and anticholinergic effects. Toxic exposure could result in severe drowsiness, impaired coordination, reduced consciousness, respiratory depression, cardiovascular changes, and neurological disturbances. The clinical severity depended on the quantity taken and could have been greater when oxomemazine was combined with alcohol or other medicines that produced central nervous system depression. Suspected serious toxicity required prompt medical assessment and supportive treatment.